The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX).
L. Dahan
No relevant relationships to disclose
B. Chibaudel
No relevant relationships to disclose
F. Di Fiore
No relevant relationships to disclose
P. Artru
No relevant relationships to disclose
L. Mineur
No relevant relationships to disclose
M. Galais
No relevant relationships to disclose
O. Dupuis
No relevant relationships to disclose
V. Blondin
No relevant relationships to disclose
S. Abdiche
No relevant relationships to disclose
M. Attia
No relevant relationships to disclose
A. De Gramont
No relevant relationships to disclose
G. Lledo
No relevant relationships to disclose